| REVIEW ARTICLE |
|
| Year : 2022 | Volume
: 13
| Issue : 4 | Page : 211-215 |
|
|
Naltrexone beyond psychiatric domain
Ashutosh Garg, Khyati Thapliyal, Vivek Pal Singh
Department of Internal Medicine, BLK-Max Super Speciality Hospital, New Delhi, India
Correspondence Address:
Dr. Vivek Pal Singh
Department of Internal Medicine, BLK-Max Super Speciality Hospital, New Delhi
India
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/injms.injms_35_22
|
|
|
Naltrexone, an opioid receptor (OR) antagonist, at its standard doses, is a United States Federal Drug Administration-approved drug for opioid and alcohol use disorders. However, with the discovery of nonneuropsychiatric effects of OR signaling with low-dose naltrexone, it has found novel applications in inflammatory, malignant, insulin sensitivity-related, and chronic pain conditions. Lower doses also ameliorate its adverse effects. Its off-label use in the abovementioned situations has proven to be cost-effective against costly immunomodulating and antineoplastic drugs. Its lower cost and miniscule margin of interest have precluded in-depth analysis by the pharmaceutical industry. So far, only animal studies, cell culture studies, and case reports have been conducted, some of which exhibit promising benefits. There is a dearth of much-needed quality trials.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
